Zogenix (ZGNX) Stock Price
Zogenix Price
Revenue has compounded at 12.0% per year over the past 11 years to 81.69 M USD. Zogenix's net margin stands at -278.4%, down from -241.6% several years earlier.
Zogenix stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Zogenix over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Zogenix stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Zogenix's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Zogenix Price |
|---|
Zogenix Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Zogenix Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e | 2025e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.00 | 37.00 | 44.00 | 33.00 | 40.00 | 27.00 | 28.00 | 9.00 | – | 3.00 | 13.00 | 81.00 | 172.00 | 329.00 | 602.00 | 837.00 |
| – | 60.87 | 18.92 | -25.00 | 21.21 | -32.50 | 3.70 | -67.86 | – | – | 333.33 | 523.08 | 112.35 | 91.28 | 82.98 | 39.04 |
| 39.13 | 45.95 | 52.27 | 30.30 | 20.00 | 14.81 | 21.43 | 844.44 | – | 100.00 | 100.00 | 93.83 | 93.83 | 93.83 | 93.83 | 93.83 |
| 9.00 | 17.00 | 23.00 | 10.00 | 8.00 | 4.00 | 6.00 | 76.00 | 76.00 | 3.00 | 13.00 | 76.00 | 161.38 | 308.69 | 564.84 | 785.33 |
| -70.00 | -76.00 | -47.00 | -52.00 | -99.00 | -49.00 | -67.00 | -94.00 | -141.00 | -429.00 | -247.00 | -212.00 | -167.00 | -43.00 | -62.00 | -93.00 |
| -304.35 | -205.41 | -106.82 | -157.58 | -247.50 | -181.48 | -239.29 | -1,044.44 | – | -14,300.00 | -1,900.00 | -261.73 | -97.09 | -13.07 | -10.30 | -11.11 |
| -73.00 | -83.00 | -47.00 | -80.00 | 8.00 | 26.00 | -69.00 | -126.00 | -123.00 | -419.00 | -209.00 | -227.00 | -165.00 | -44.00 | -56.00 | -86.00 |
| 62.22 | 13.70 | -43.37 | 70.21 | -110.00 | 225.00 | -365.38 | 82.61 | -2.38 | 240.65 | -50.12 | 8.61 | -27.31 | -73.33 | 27.27 | 53.57 |
| 1.00 | 5.00 | 10.00 | 14.00 | 18.00 | 21.00 | 25.00 | 27.00 | 38.00 | 43.00 | 54.00 | 56.00 | 56.00 | 56.00 | 56.00 | 56.00 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Zogenix generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Zogenix retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Zogenix's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Zogenix has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Zogenix's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Zogenix stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Zogenix Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Zogenix business model & stock analysis
Zogenix SWOT Analysis
Strengths
Zogenix Inc has several key strengths that contribute to its success:
- Strong product portfolio, including innovative and effective pharmaceuticals.
- A solid reputation for research and development, leading to breakthrough treatments.
- Strong financial position, enabling investment in new technologies and growth opportunities.
- An experienced and knowledgeable team of professionals dedicated to improving patient outcomes.
Weaknesses
Despite its strengths, Zogenix Inc also faces certain weaknesses:
- Limited market presence compared to larger pharmaceutical companies.
- Reliance on a limited number of products for revenue generation.
- Higher production costs compared to competitors, impacting profit margins.
- Vulnerability to regulatory changes and challenges in obtaining necessary approvals.
Opportunities
Zogenix Inc has several opportunities for growth and expansion:
- Exploring new markets and geographic regions for product distribution.
- Expanding the company's product pipeline through strategic partnerships and acquisitions.
- Investing in research and development to create innovative treatments for unmet medical needs.
- Capitalizing on the growing demand for specialized pharmaceuticals worldwide.
Threats
Zogenix Inc faces certain threats that may impact its business:
- Intense competition from both established pharmaceutical companies and emerging startups.
- Increasing regulatory scrutiny and a complex approval process for new drugs.
- Economic downturns and pricing pressures affecting the pharmaceutical industry.
- Risks associated with potential lawsuits and legal challenges.
Zogenix Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Zogenix Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Zogenix historical P/E ratio, EBIT multiple, and P/S ratio
Zogenix annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Zogenix shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Zogenix stock splits
Zogenix Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 1/19/2022 | Downgrade | BuyHold | 70 | |
| 12/20/2021 | Maintained | Outperform | – | |
| 9/9/2021 | Maintained | Buy | 51 | |
| 8/6/2021 | Maintained | Outperform | – | |
| 8/6/2021 | Maintained | Buy | 70 | |
| 8/25/2020 | Maintained | Market PerformPerform | 74 | |
| 6/29/2020 | Maintained | Buy | 70 | |
| 5/6/2020 | Maintained | Buy | 70 | |
| 4/1/2020 | Maintained | Buy | 31 | |
| 3/6/2020 | Maintained | Neutral | 48 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Zogenix Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/29/2022 | -0.51USD | - | 60.98 MUSD | - | 2022 Q3 |
| 10/4/2022 | -0.77USD | - | 35.50 MUSD | - | 2022 Q2 |
| 5/4/2022 | -0.87USD | - | 29.78 MUSD | - | 2022 Q1 |
| 2/28/2022 | -0.90USD | - | 26.80 MUSD | - | 2021 Q4 |
| 11/4/2021 | -0.99USD | - | 22.66 MUSD | - | 2021 Q3 |
| 8/5/2021 | -0.95USD | - | 17.27 MUSD | - | 2021 Q2 |
| 5/6/2021 | -1.04USD | - | 12.52 MUSD | - | 2021 Q1 |
| 2/25/2021 | -1.02USD | - | 7.72 MUSD | - | 2020 Q4 |
| 11/9/2020 | -1.00USD | - | 2.55 MUSD | - | 2020 Q3 |
| 8/5/2020 | -1.02USD | - | 553,073.00USD | - | 2020 Q2 |
Zogenix shareholder structure
| % | Name |
|---|---|
7.30639% | |
7.25652% | |
7.07051% | |
6.41317% | |
5.95410% | |
5.73291% |
Zogenix Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
17.60% | SEC ↗ | |
17.60% | SEC ↗ | |
17.60% | SEC ↗ | |
17.60% | SEC ↗ | |
17.60% | SEC ↗ | |
17.60% | SEC ↗ | |
17.60% | SEC ↗ | |
17.60% | SEC ↗ | |
12.16% | SEC ↗ | |
12.16% | SEC ↗ |
Zogenix Executives and Management Board
28 members · avg. age 59 · 32 % women
Dr. Stephen Farr (62)
President, Chief Executive Officer, Director · since 2015
4.75 M USD
Management
Ms. Shawnte Mitchell (43)
Executive Vice President, General Counsel, Secretary · since 2020
Mr. Ashish Sagrolikar (54)
Executive Vice President, Chief Commercial Officer · since 2018
Dr. Bradley Galer (58)
Executive Vice President, Chief Medical Officer · since 2013
Mr. Michael Smith (52)
Chief Financial Officer, Executive Vice President, Treasurer, Secretary · since 2017
Dr. Gail Farfel (56)
Executive Vice President, Chief Development Officer · since 2015
Dr. Thierry Darcis
Executive Vice President and General Manager of Europe of Brabant Pharma Ltd. · since 2015
Board of Directors
Mr. Cam Garner (72)
Independent Chairman of the Board · since 2006
Mr. Erle Mast (58)
Independent Director · since 2008
Ms. Caroline Loewy (54)
Independent Director · since 2020
Ms. Mary Stutts (65)
Independent Director · since 2020
Ms. Denelle Waynick (53)
Independent Director · since 2020
Mr. Louis Bock (56)
Independent Director · since 2017
Frequently asked questions about Zogenix
The business model of Zogenix Inc revolves around the development and commercialization of innovative therapies for patients with rare neurological disorders. With a focus on advancing treatments for orphan diseases, Zogenix combines scientific expertise, research, and strategic partnerships to deliver transformative solutions. The company's portfolio includes FDA-approved medications targeting specific conditions such as Dravet syndrome, in addition to ongoing clinical trials for other disorders. By prioritizing patient needs and leveraging its expertise in the field, Zogenix aims to make a positive impact on the lives of those suffering from rare neurological disorders.
Zogenix Inc is primarily active in the pharmaceutical industry, specifically focusing on the development and commercialization of transformative therapies for central nervous system disorders.
The main competitors of Zogenix Inc in the market are other pharmaceutical companies specializing in the development and commercialization of therapies for central nervous system disorders, such as Biogen Inc, Jazz Pharmaceuticals, and Supernus Pharmaceuticals.
Zogenix Inc is a pharmaceutical company with a rich history and background. Founded in 2006, the company focuses on discovering and developing therapies for rare central nervous system disorders. Over the years, Zogenix has successfully introduced innovative treatments and made significant contributions to the medical field. With a strong commitment to improving patients' lives, Zogenix Inc has obtained FDA approvals for medications addressing conditions such as Dravet syndrome and Lennox-Gastaut syndrome. The company's continuous research and dedication to bringing novel therapies to market highlight its position as a leader in the pharmaceutical industry.
Some significant milestones that Zogenix Inc has achieved include the FDA approval of their drug, Fintepla, for the treatment of seizures associated with Dravet syndrome. This milestone marked a major breakthrough in providing a therapeutic option for patients with this rare form of epilepsy. Additionally, the company has successfully completed clinical trials and achieved positive results for their other pipeline products, further showcasing their commitment to innovation and medical advancements. Zogenix Inc's continued dedication to improving the lives of patients has positioned them as a prominent player in the pharmaceutical industry.
Zogenix Inc is primarily present in the United States.
Zogenix Inc represents a strong commitment to improving the lives of patients through innovative therapies. The company is focused on developing and commercializing transformative medicines that address unmet medical needs. Zogenix Inc values patient-centricity, scientific excellence, and ethical decision-making. By prioritizing innovation and collaboration, Zogenix Inc strives to provide effective treatment options for individuals facing challenging health conditions. With a dedicated team and a mission-driven approach, Zogenix Inc works towards enhancing patient outcomes and contributing to the advancement of medical science.
15 analysts currently rate the Zogenix stock: 7 recommend buying, 8 holding and 0 selling.
The Zogenix share (ZGNX) is listed on 1 stock exchanges, including: NASDAQ (ZGNX).
Zogenix Inc is a US-based biopharmaceutical company that focuses on the development and marketing of therapies for serious diseases with high medical needs. The company was founded in 2006 and is headquartered in Emeryville, California.
The revenue cannot currently be calculated for Zogenix.
The profit cannot currently be calculated for Zogenix.
The P/E ratio cannot be calculated for Zogenix at the moment.
The P/S cannot be calculated for Zogenix currently.
The Eulerpool Quality Score for Zogenix is 4/10.
The ISIN of Zogenix is US98978L2043. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Zogenix is A14V7E. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Zogenix is ZGNX. The ticker symbol is used to trade Zogenix shares on the stock exchange.
Zogenix is assigned to the 'Health' sector.
The dividends of Zogenix are distributed in USD.
Zogenix stock
Zogenix Peer Group
Zogenix Ticker
Zogenix FIGI
All fundamentals and in-depth analysis of Zogenix
Our stock analysis for Zogenix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zogenix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.